STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced the first patient treatment using the Hummingbird Solo,
an additional line extension to its innovative Hummingbird ICP
Monitoring product family that was launched in December of last
year. Hummingbird Solo is a single-lumen, bolt-based monitor
that measures the pressure within a patient's brain tissue and
helps diagnose and manage patients' intracranial pressure (ICP)
after traumatic brain injury (TBI), a subarachnoid hemorrhage, or
stroke.
The first Hummingbird Solo patient was treated by a team, led by
neurosurgeon Dr. Andrew Carlson, at
the University of New Mexico (UNM)
Hospital, located in Albuquerque, New
Mexico.
"The Hummingbird Solo bolt's simple insertion and set up allow
us to quickly and confidently monitor critically ill patients who
suffer from traumatic brain injury," said Dr. Carlson, assistant
professor of neurological surgery, UNM Hospital. "Our mission at
UNM Hospital is to provide our patients with the best quality in
healthcare, and we are proud to be the first hospital in the world
to use this next-generation technology."
Traumatic brain injury is defined as an impact to the head that
disrupts the normal function of the brain. Worldwide, TBI is a
leading cause of injury-related death and disability, with a
devastating impact on patients and their families. It is estimated
that the lifetime economic cost of TBI in the US alone, including
direct and indirect medical costs, is over $75 billion.1 In the United States and European Union,
approximately 5.4 million people each year are affected by TBI, and
1.3 million experience injuries severe enough to require
hospitalization.2
"Today marks a significant milestone for IRRAS as we celebrate
the first patient treatment with the Hummingbird Solo product
line," said Will Martin, President
and Chief Commercial Officer of IRRAS. "This line extension to the
Hummingbird product family offers a unique and simplified
monitoring solution for neurocritical care specialists, and we
believe that Hummingbird Solo can grow into a market leader in the
global ICP monitoring market."
Assessment of a patient's ICP is a critical element of managing
TBI, and the Hummingbird Solo is designed to continuously monitor a
patient's ICP by placing a small sensor directly into the brain
tissue. Instead of using strain gauge or fiberoptic sensors like
other ICP monitors, the Hummingbird system uses a small air bladder
that allows simple setup and automatic, hourly ICP recalibration.
This air bladder mechanism of action eliminates challenges that
plague other systems, including cumbersome setup and ICP readings
that cannot be recalibrated and become increasingly inaccurate over
time.
Physicians or hospitals in the United
States who are interested in learning more about IRRAS or
the Hummingbird ICP Monitoring product line should contact their
local IRRAS sales professional or info@irras.com for
additional information. IRRAS' team of direct sales professionals
is available to provide support, training, and certification for
the company's entire product family, including Hummingbird ICP and
IRRAflow.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring
product lines to hospitals worldwide through its direct sales
organization in the United States
and select European countries as well as an international network
of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker:
IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos,
Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46-73-951-95-02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on August 11, 2020 at 10:00
(CET).
1. Severe TBI. Centers for Disease Control
and Prevention, Centers for Disease Control and Prevention,
2 Apr. 2019,
www.cdc.gov/traumaticbraininjury/severe.html.
2. Traumatic Brain Injury Fact sheets and Policy
brief. Center-TBI,
https://www.center-tbi.eu/files/news/21571f81-20b8-4860-a3dd-1f6e27d02b3d.pdf.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-first-global-patient-treatment-with-newly-developed-hummingbird-solo-icp-monitoring-,c3166726
View original
content:http://www.prnewswire.com/news-releases/irras-announces-first-global-patient-treatment-with-newly-developed-hummingbird-solo-icp-monitoring-system-301109743.html
SOURCE IRRAS